Cytochrome P450, family 3, subfamily A, also known as CYP3A, is a human gene.
The CYP3A locus includes all the known members of the 3A subfamily of the cytochrome P450 superfamily of genes. These genes encode monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The CYP3A cluster consists of four genes:
as well as several extra exons which may or may not be included in transcripts produced from this region. Previously another CYP3A member, CYP3A3, was thought to exist; however, it is now thought that this sequence represents a transcript variant of CYP3A4.
Miyazawa M, Shindo M, Shimada T (2002). "Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-cineole, a monoterpene cyclic ether, by rat and human liver microsomes". Xenobiotica31 (10): 713–23. doi:10.1080/00498250110065595. PMID11695850.
Reid JM, Kuffel MJ, Ruben SL et al. (2002). "Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans". Clin. Cancer Res.8 (9): 2952–62. PMID12231541.
Dowling TC, Briglia AE, Fink JC et al. (2003). "Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease". Clin. Pharmacol. Ther.73 (5): 427–34. doi:10.1016/S0009-9236(03)00056-0. PMID12732843.
Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD (2004). "Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes". Drug Metab. Dispos.32 (3): 359–63. doi:10.1124/dmd.32.3.359. PMID14977871.
Somogyi AA, Menelaou A, Fullston SV (2005). "CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement". Xenobiotica34 (10): 875–87. doi:10.1080/00498250400008371. PMID15764408.
Thompson EE, Kuttab-Boulos H, Yang L et al. (2006). "Sequence diversity and haplotype structure at the human CYP3A cluster". Pharmacogenomics J.6 (2): 105–14. doi:10.1038/sj.tpj.6500347. PMID16314882.
Cheung CY, Op den Buijsch RA, Wong KM et al. (2006). "Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients". Pharmacogenomics7 (4): 563–74. doi:10.2217/146224126.96.36.1993. PMID16753004.
Kirby B, Kharasch ED, Thummel KT et al. (2007). "Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities". Journal of clinical pharmacology46 (11): 1313–9. doi:10.1177/0091270006292625. PMID17050796.
He P, Court MH, Greenblatt DJ, von Moltke LL (2007). "Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity". Journal of clinical pharmacology46 (11): 1356–69. doi:10.1177/0091270006292125. PMID17050801.
Watanabe A, Nakamura K, Okudaira N et al. (2007). "Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process". Drug Metab. Dispos.35 (7): 1232–8. doi:10.1124/dmd.107.015016. PMID17392390.
Kharasch ED, Walker A, Isoherranen N et al. (2007). "Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam". Clin. Pharmacol. Ther.82 (4): 410–26. doi:10.1038/sj.clpt.6100237. PMID17554244.